MedTrace Logo

Effect of Modified Citrus Pectin on PSA Kinetics in Biochemical Relapsed PC With Serial Increases in PSA

NCT01681823 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-01-29

No results posted yet for this study

Summary

To determine if the oral administration of PectaSol-C Modified Citrus Pectin (MCP) is effective at improving Prostate Specific Antigen (PSA) kinetics in men with biochemical relapsed prostate cancer and serial increases in PSA levels. Also, documentation of any side effects or benefits within parameter of the study is included.

Conditions

  • Prostatic Neoplasms

Interventions

DIETARY_SUPPLEMENT

PectaSol-C Modified Citrus Pectin (MCP)

Oral administration of PectaSol-C MCP (4.8 grams in six capsules three times a day away from food).

Sponsors & Collaborators

  • EcoNugenics

    lead INDUSTRY

Principal Investigators

  • Daniel Keizman, MD · Genitourinary Oncology Service, Institute of Oncology, Meir Medical Center

  • Isaac Eliaz, MD, LAc, MS · Amitabha Medical Clinic and Healing Center

  • Moshe Frenkel, MD · Clinical Associate Professor, University of Texas

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2020-01-31
Completion
2020-01-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01681823 on ClinicalTrials.gov